{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:42:52Z","timestamp":1791474172422,"version":"4.3.4"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12016-021-08868-z","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T15:32:30Z","timestamp":1626795150000},"page":"299-323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-9522","authenticated-orcid":false,"given":"Yinghan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2335-507X","authenticated-orcid":false,"given":"Shuli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3004-5376","authenticated-orcid":false,"given":"Chunying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"8868_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","volume":"38","author":"ML Frisoli","year":"2020","unstructured":"Frisoli ML, Essien K, Harris JE (2020) Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol 38:621\u2013648. https:\/\/doi.org\/10.1146\/annurev-immunol-100919-023531","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"8868_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","volume":"54","author":"K Boniface","year":"2018","unstructured":"Boniface K, Seneschal J, Picardo M, Taieb A (2018) Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. Clin Rev Allergy Immunol 54(1):52\u201367. https:\/\/doi.org\/10.1007\/s12016-017-8622-7","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"8868_CR3","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","volume":"25","author":"K Ezzedine","year":"2012","unstructured":"Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, Goh BK, Anbar T, Silva de Castro C, Lee AY, Parsad D, van Geel N, Le Poole IC, Oiso N, Benzekri L, Spritz R, Gauthier Y, Hann SK, Picardo M, Taieb A, Conference VGIC P (2012) Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 25(3):E1-13. https:\/\/doi.org\/10.1111\/j.1755-148X.2012.00997.x","journal-title":"Pigment Cell Melanoma Res"},{"key":"8868_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-01808-5","author":"C Schmidt","year":"2020","unstructured":"Schmidt C (2020) Temprian therapeutics: developing a gene-based treatment for vitiligo. Nature. https:\/\/doi.org\/10.1038\/d41586-020-01808-5","journal-title":"Nature"},{"issue":"9988","key":"8868_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, van Geel N (2015) Vitiligo Lancet 386(9988):74\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(14)60763-7","journal-title":"Vitiligo Lancet"},{"issue":"3","key":"8868_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaci.2017.07.011","volume":"140","author":"ML Frisoli","year":"2017","unstructured":"Frisoli ML, Harris JE (2017) Vitiligo: mechanistic insights lead to novel treatments. J Allergy Clin Immunol 140(3):654\u2013662. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.011","journal-title":"J Allergy Clin Immunol"},{"key":"8868_CR7","doi-asserted-by":"publisher","unstructured":"Cui T, Zhang W, Li S, Chen X, Chang Y, Yi X, Kang P, Yang Y, Chen J, Liu L, Jian Z, Li K, Wang G, Gao T, Song P, Li C (2019) Oxidative stress-induced HMGB1 release from melanocytes: a paracrine mechanism underlying the cutaneous inflammation in vitiligo. J Invest Dermatol 139 (10):2174\u20132184 e2174. https:\/\/doi.org\/10.1016\/j.jid.2019.03.1148","DOI":"10.1016\/j.jid.2019.03.1148"},{"key":"8868_CR8","doi-asserted-by":"publisher","unstructured":"Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman CJ, Lacek AT, Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, Mehrotra S, Hernandez C, Nishimura MI, Guevara-Patino JA, Le Poole IC (2013) Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med 5 (174):174ra128. https:\/\/doi.org\/10.1126\/scitranslmed.3005127","DOI":"10.1126\/scitranslmed.3005127"},{"issue":"1","key":"8868_CR9","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/s41467-019-09963-8","volume":"10","author":"MK Tulic","year":"2019","unstructured":"Tulic MK, Cavazza E, Cheli Y, Jacquel A, Luci C, Cardot-Leccia N, Hadhiri-Bzioueche H, Abbe P, Gesson M, Sormani L, Regazzetti C, Beranger GE, Lereverend C, Pons C, Khemis A, Ballotti R, Bertolotto C, Rocchi S, Passeron T (2019) Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo. Nat Commun 10(1):2178. https:\/\/doi.org\/10.1038\/s41467-019-09963-8","journal-title":"Nat Commun"},{"issue":"3","key":"8868_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaad.2019.07.036","volume":"82","author":"A Hadi","year":"2020","unstructured":"Hadi A, Wang JF, Uppal P, Penn LA, Elbuluk N (2020) Comorbid diseases of vitiligo: a 10-year cross-sectional retrospective study of an urban US population. J Am Acad Dermatol 82(3):628\u2013633. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.036","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"8868_CR11","doi-asserted-by":"publisher","first-page":"e1664","DOI":"10.1212\/WNL.0000000000009242","volume":"94","author":"F Han","year":"2020","unstructured":"Han F, Ren H, Tang M, Zhu Y, Guan H (2020) Clinical reasoning: a 47-year-old man with rapidly progressive ataxia and vitiligo. Neurology 94(15):e1664\u2013e1669. https:\/\/doi.org\/10.1212\/WNL.0000000000009242","journal-title":"Neurology"},{"key":"8868_CR12","doi-asserted-by":"publisher","first-page":"5617838","DOI":"10.1155\/2017\/5617838","volume":"2017","author":"V Vachiramon","year":"2017","unstructured":"Vachiramon V, Onprasert W, Harnchoowong S, Chanprapaph K (2017) Prevalence and clinical characteristics of itch in vitiligo and its clinical significance. Biomed Res Int 2017:5617838. https:\/\/doi.org\/10.1155\/2017\/5617838","journal-title":"Biomed Res Int"},{"issue":"3","key":"8868_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaad.2009.03.022","volume":"61","author":"MW Linthorst Homan","year":"2009","unstructured":"Linthorst Homan MW, Spuls PI, de Korte J, Bos JD, Sprangers MA, van der Veen JP (2009) The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 61(3):411\u2013420. https:\/\/doi.org\/10.1016\/j.jaad.2009.03.022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8868_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.clindermatol.2017.01.001","volume":"35","author":"F Cupertino","year":"2017","unstructured":"Cupertino F, Niemeyer-Corbellini JP, Ramos ESM (2017) Psychosomatic aspects of vitiligo. Clin Dermatol 35(3):292\u2013297. https:\/\/doi.org\/10.1016\/j.clindermatol.2017.01.001","journal-title":"Clin Dermatol"},{"issue":"1","key":"8868_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210581","volume":"14","author":"D Chen","year":"2019","unstructured":"Chen D, Tuan H, Zhou EY, Liu D, Zhao Y (2019) Quality of life of adult vitiligo patients using camouflage: a survey in a Chinese vitiligo community. PLoS One 14(1):e0210581. https:\/\/doi.org\/10.1371\/journal.pone.0210581","journal-title":"PLoS ONE"},{"issue":"5","key":"8868_CR16","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/1346-8138.15290","volume":"47","author":"CY Chen","year":"2020","unstructured":"Chen CY, Wang WM, Chung CH, Tsao CH, Chien WC, Hung CT (2020) Increased risk of psychiatric disorders in adult patients with vitiligo: a nationwide, population-based cohort study in Taiwan. J Dermatol 47(5):470\u2013475. https:\/\/doi.org\/10.1111\/1346-8138.15290","journal-title":"J Dermatol"},{"issue":"8","key":"8868_CR17","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/jdv.14739","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Qiu D, Yang H, Liu W (2018) The prevalence and odds of depression in patients with vitiligo: a meta-analysis. J Eur Acad Dermatol Venereol 32(8):1343\u20131351. https:\/\/doi.org\/10.1111\/jdv.14739","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"8868_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241445","volume":"15","author":"A Kussainova","year":"2020","unstructured":"Kussainova A, Kassym L, Akhmetova A, Glushkova N, Sabirov U, Adilgozhina S, Tuleutayeva R, Semenova Y (2020) Vitiligo and anxiety: a systematic review and meta-analysis. PLoS One 15(11):e0241445. https:\/\/doi.org\/10.1371\/journal.pone.0241445","journal-title":"PLoS ONE"},{"key":"8868_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14196","author":"I Ucuz","year":"2020","unstructured":"Ucuz I, Altunisik N, Sener S, Turkmen D, Kavuran NA, Marsak M, Colak C (2020) Quality of life, emotion dysregulation, attention deficit and psychiatric comorbidity in children and adolescents with vitiligo. Clin Exp Dermatol. https:\/\/doi.org\/10.1111\/ced.14196","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"8868_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/jdv.15255","volume":"33","author":"KR Patel","year":"2019","unstructured":"Patel KR, Singam V, Rastogi S, Lee HH, Silverberg NB, Silverberg JI (2019) Association of vitiligo with hospitalization for mental health disorders in US adults. J Eur Acad Dermatol Venereol 33(1):191\u2013197. https:\/\/doi.org\/10.1111\/jdv.15255","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"8868_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12955-020-1278-7","volume":"18","author":"N Hamidizadeh","year":"2020","unstructured":"Hamidizadeh N, Ranjbar S, Ghanizadeh A, Parvizi MM, Jafari P, Handjani F (2020) Evaluating prevalence of depression, anxiety and hopelessness in patients with vitiligo on an Iranian population. Health Qual Life Outcomes 18(1):20. https:\/\/doi.org\/10.1186\/s12955-020-1278-7","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"8868_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3892\/etm.2019.8145","volume":"20","author":"A Maria Alexandra Stanescu","year":"2020","unstructured":"Maria Alexandra Stanescu A, Totan A, Mircescu D, Diaconescu S, Gabriel Bratu O, Fekete L, Laszlo Fekete G, Boda D, Cristina Diaconu C (2020) Assessment of suicidal behavior in dermatology (review). Exp Ther Med 20(1):73\u201377. https:\/\/doi.org\/10.3892\/etm.2019.8145","journal-title":"Exp Ther Med"},{"issue":"3","key":"8868_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2340\/00015555-1940","volume":"95","author":"AA Amer","year":"2015","unstructured":"Amer AA, McHepange UO, Gao XH, Hong Y, Qi R, Wu Y, Cai Y, Zhai J, Chen HD (2015) Hidden victims of childhood vitiligo: impact on parents\u2019 mental health and quality of life. Acta Derm Venereol 95(3):322\u2013325. https:\/\/doi.org\/10.2340\/00015555-1940","journal-title":"Acta Derm Venereol"},{"key":"8868_CR24","doi-asserted-by":"publisher","first-page":"3495165","DOI":"10.1155\/2020\/3495165","volume":"2020","author":"AG Tsadik","year":"2020","unstructured":"Tsadik AG, Teklemedhin MZ, Mehari Atey T, Gidey MT, Desta DM (2020) Public knowledge and attitudes towards vitiligo: a survey in Mekelle City. Northern Ethiopia Dermatol Res Pract 2020:3495165. https:\/\/doi.org\/10.1155\/2020\/3495165","journal-title":"Northern Ethiopia Dermatol Res Pract"},{"key":"8868_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.088","author":"JM Bae","year":"2020","unstructured":"Bae JM, Kim JE, Lee RW, Ju HJ, Han JH, Lee JH, Woo YR, Lee JH, Bang CH, Park CJ, Ezzedine K, Kim M (2020) Beyond the quality of life: a call for patients\u2019 own willingness to pay in chronic skin disease to assess psychosocial burden: a multi-center, cross-sectional prospective survey. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.088","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"8868_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163806","volume":"11","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Cai Y, Shi M, Jiang S, Cui S, Wu Y, Gao XH, Chen HD (2016) The prevalence of vitiligo: a meta-analysis. PLoS One 11(9):e0163806. https:\/\/doi.org\/10.1371\/journal.pone.0163806","journal-title":"PLoS ONE"},{"issue":"1","key":"8868_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2340\/00015555-1397","volume":"93","author":"X Wang","year":"2013","unstructured":"Wang X, Du J, Wang T, Zhou C, Shen Y, Ding X, Tian S, Liu Y, Peng G, Xue S, Zhou J, Wang R, Meng X, Pei G, Bai Y, Liu Q, Li H, Zhang J (2013) Prevalence and clinical profile of vitiligo in China: a community-based study in six cities. Acta Derm Venereol 93(1):62\u201365. https:\/\/doi.org\/10.2340\/00015555-1397","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"8868_CR28","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1046\/j.1365-4362.2003.01936.x","volume":"42","author":"K Abdel-Hafez","year":"2003","unstructured":"Abdel-Hafez K, Abdel-Aty MA, Hofny ER (2003) Prevalence of skin diseases in rural areas of Assiut Governorate. Upper Egypt Int J Dermatol 42(11):887\u2013892. https:\/\/doi.org\/10.1046\/j.1365-4362.2003.01936.x","journal-title":"Upper Egypt Int J Dermatol"},{"issue":"1","key":"8868_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-4632.2006.02848.x","volume":"46","author":"T Lu","year":"2007","unstructured":"Lu T, Gao T, Wang A, Jin Y, Li Q, Li C (2007) Vitiligo prevalence study in Shaanxi Province. China Int J Dermatol 46(1):47\u201351. https:\/\/doi.org\/10.1111\/j.1365-4632.2006.02848.x","journal-title":"China Int J Dermatol"},{"issue":"4","key":"8868_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40257-019-00430-0","volume":"20","author":"E Nicolaidou","year":"2019","unstructured":"Nicolaidou E, Mastraftsi S, Tzanetakou V, Rigopoulos D (2019) Childhood vitiligo. Am J Clin Dermatol 20(4):515\u2013526. https:\/\/doi.org\/10.1007\/s40257-019-00430-0","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"8868_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41467-019-08337-4","volume":"10","author":"Y Jin","year":"2019","unstructured":"Jin Y, Roberts GHL, Ferrara TM, Ben S, van Geel N, Wolkerstorfer A, Ezzedine K, Siebert J, Neff CP, Palmer BE, Santorico SA, Spritz RA (2019) Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. Nat Commun 10(1):391. https:\/\/doi.org\/10.1038\/s41467-019-08337-4","journal-title":"Nat Commun"},{"key":"8868_CR32","doi-asserted-by":"publisher","unstructured":"Jin Y, Santorico SA, Spritz RA (2020) Pediatric to adult shift in vitiligo onset suggests altered environmental triggering. J Invest Dermatol 140 (1):241\u2013243 e244. https:\/\/doi.org\/10.1016\/j.jid.2019.06.131","DOI":"10.1016\/j.jid.2019.06.131"},{"key":"8868_CR33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jama.1939.72800350003010a","volume":"113","author":"EA Oliver","year":"1939","unstructured":"Oliver EA, Schwartz L, Warren LH (1939) Occupational leukoderma. JAMA 113:927\u2013928","journal-title":"JAMA"},{"issue":"2","key":"8868_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.det.2016.11.006","volume":"35","author":"JE Harris","year":"2017","unstructured":"Harris JE (2017) Chemical-induced vitiligo. Dermatol Clin 35(2):151\u2013161. https:\/\/doi.org\/10.1016\/j.det.2016.11.006","journal-title":"Dermatol Clin"},{"issue":"8050","key":"8868_CR35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/s0140-6736(77)90451-2","volume":"2","author":"O James","year":"1977","unstructured":"James O, Mayes RW, Stevenson CJ (1977) Occupational vitiligo induced by p-tert-butylphenol, a systemic disease? Lancet 2(8050):1217\u20131219. https:\/\/doi.org\/10.1016\/s0140-6736(77)90451-2","journal-title":"Lancet"},{"issue":"6","key":"8868_CR36","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.mayocp.2020.02.012","volume":"95","author":"H Shakshouk","year":"2020","unstructured":"Shakshouk H, Lehman JS (2020) Chemical-associated vitiligo. Mayo Clin Proc 95(6):1105\u20131106. https:\/\/doi.org\/10.1016\/j.mayocp.2020.02.012","journal-title":"Mayo Clin Proc"},{"key":"8868_CR37","doi-asserted-by":"publisher","unstructured":"Taieb A, Picardo M (2009) Clinical practice. vitiligo. N Engl J Med 360 (2):160\u2013169. https:\/\/doi.org\/10.1056\/NEJMcp0804388","DOI":"10.1056\/NEJMcp0804388"},{"issue":"6","key":"8868_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/dth.12151","volume":"27","author":"L Mavilia","year":"2014","unstructured":"Mavilia L, Mercuri SR (2014) Koebner\u2019s phenomenon induced vitiligo following Nd:YAG laser epilation treatment in a woman with a past history of a Sutton nevus. Dermatol Ther 27(6):355\u2013356. https:\/\/doi.org\/10.1111\/dth.12151","journal-title":"Dermatol Ther"},{"issue":"3","key":"8868_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1468-3083.2008.02844.x","volume":"23","author":"SB Verma","year":"2009","unstructured":"Verma SB (2009) Vitiligo precipitated by striae: a little known entity. J Eur Acad Dermatol Venereol 23(3):357\u2013358. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02844.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"8868_CR40","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1111\/1346-8138.14514","volume":"46","author":"SH Eun","year":"2019","unstructured":"Eun SH, Lee JH, Kim GM, Kim KH, Bae JM (2019) Vitiligo at a keloid scar: a possible case of koebner phenomenon. J Dermatol 46(1):e28\u2013e29. https:\/\/doi.org\/10.1111\/1346-8138.14514","journal-title":"J Dermatol"},{"issue":"6","key":"8868_CR41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41419-020-2665-z","volume":"11","author":"T Zhuang","year":"2020","unstructured":"Zhuang T, Yi X, Chen J, Kang P, Chen X, Chen J, Cui T, Chang Y, Ye Z, Ni Q, Wang Y, Du P, Li B, Liu L, Jian Z, Li K, Gao T, Li S, Li C (2020) Intracellular virus sensor MDA5 exacerbates vitiligo by inducing the secretion of chemokines in keratinocytes under virus invasion. Cell Death Dis 11(6):453. https:\/\/doi.org\/10.1038\/s41419-020-2665-z","journal-title":"Cell Death Dis"},{"issue":"6","key":"8868_CR42","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1346-8138.2000.tb02196.x","volume":"27","author":"T Yamamoto","year":"2000","unstructured":"Yamamoto T, Nishioka K (2000) Vitiligo vulgaris associated with hepatitis C virus. J Dermatol 27(6):416\u2013417. https:\/\/doi.org\/10.1111\/j.1346-8138.2000.tb02196.x","journal-title":"J Dermatol"},{"issue":"8","key":"8868_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1346-8138.2006.00135.x","volume":"33","author":"H Tsuboi","year":"2006","unstructured":"Tsuboi H, Yonemoto K, Katsuoka K (2006) Vitiligo with inflammatory raised borders with hepatitis C virus infection. J Dermatol 33(8):577\u2013578. https:\/\/doi.org\/10.1111\/j.1346-8138.2006.00135.x","journal-title":"J Dermatol"},{"issue":"6","key":"8868_CR44","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jid.2017.02.004","volume":"137","author":"R Dunlap","year":"2017","unstructured":"Dunlap R, Wu S, Wilmer E, Cho E, Li WQ, Lajevardi N, Qureshi A (2017) Pigmentation traits, sun exposure, and risk of incident vitiligo in women. J Invest Dermatol 137(6):1234\u20131239. https:\/\/doi.org\/10.1016\/j.jid.2017.02.004","journal-title":"J Invest Dermatol"},{"issue":"5","key":"8868_CR45","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/bjd.12162","volume":"168","author":"C Vrijman","year":"2013","unstructured":"Vrijman C, Hosseinpour D, Bakker JG, Wolkerstorfer A, Bos JD, van der Veen JP, Luiten RM (2013) Provoking factors, including chemicals, in Dutch patients with vitiligo. Br J Dermatol 168(5):1003\u20131011. https:\/\/doi.org\/10.1111\/bjd.12162","journal-title":"Br J Dermatol"},{"issue":"5","key":"8868_CR46","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.abd.2020.02.010","volume":"95","author":"G Paolino","year":"2020","unstructured":"Paolino G, Bearzi P, Mercuri SR (2020) Onset of vitiligo in a patient with acquired secondary hypogonadism under treatment with testosterone gel 2%: inside the pathogenesis. An Bras Dermatol 95(5):661\u2013662. https:\/\/doi.org\/10.1016\/j.abd.2020.02.010","journal-title":"An Bras Dermatol"},{"issue":"3","key":"8868_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1684\/ejd.2008.0413","volume":"18","author":"AL Kedward","year":"2008","unstructured":"Kedward AL, Gawkrodger DJ (2008) Congenital stable symmetrical type vitiligo in a patient whose mother developed vitiligo during pregnancy. Eur J Dermatol 18(3):353. https:\/\/doi.org\/10.1684\/ejd.2008.0413","journal-title":"Eur J Dermatol"},{"issue":"6","key":"8868_CR48","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/j.1365-2133.2007.07870.x","volume":"156","author":"KU Schallreuter","year":"2007","unstructured":"Schallreuter KU, Rokos H (2007) From the bench to the bedside: proton pump inhibitors can worsen vitiligo. Br J Dermatol 156(6):1371\u20131373. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07870.x","journal-title":"Br J Dermatol"},{"key":"8868_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15562","author":"PH Chiang","year":"2020","unstructured":"Chiang PH, Ng CY, Kuo TT, Hui RC, Chen CB, Lu CW, Chung WH (2020) Case of vitiligo universalis as a sequela of drug-induced hypersensitivity syndrome. J Dermatol. https:\/\/doi.org\/10.1111\/1346-8138.15562","journal-title":"J Dermatol"},{"key":"8868_CR50","doi-asserted-by":"publisher","unstructured":"Morita C, Yanase T, Shiohara T, Aoyama Y\u00a0(2018) Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome BMJ Case Rep2018.\u00a0https:\/\/doi.org\/10.1136\/bcr-2018-225528","DOI":"10.1136\/bcr-2018-225528"},{"key":"8868_CR51","doi-asserted-by":"publisher","unstructured":"Bergqvist C, Ezzedine K (2020) Vitiligo: a review. Dermatology:1\u201322. https:\/\/doi.org\/10.1159\/000506103","DOI":"10.1159\/000506103"},{"issue":"9","key":"8868_CR52","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1111\/jdv.15604","volume":"33","author":"N van Geel","year":"2019","unstructured":"van Geel N, Grine L, De Wispelaere P, Mertens D, Prinsen CAC, Speeckaert R (2019) Clinical visible signs of disease activity in vitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 33(9):1667\u20131675. https:\/\/doi.org\/10.1111\/jdv.15604","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"8868_CR53","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamadermatol.2019.4483","volume":"156","author":"L Zhang","year":"2020","unstructured":"Zhang L, Chen S, Kang Y, Wang X, Yan F, Jiang M, Wang Q, Liu Z, Zhang C, Xiang L (2020) Association of clinical markers with disease progression in patients with vitiligo from China. JAMA Dermatol 156(3):288\u2013295. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4483","journal-title":"JAMA Dermatol"},{"issue":"5","key":"8868_CR54","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jaad.2016.12.040","volume":"76","author":"L Benzekri","year":"2017","unstructured":"Benzekri L, Gauthier Y (2017) Clinical markers of vitiligo activity. J Am Acad Dermatol 76(5):856\u2013862. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.040","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"8868_CR55","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jaad.2017.05.027","volume":"77","author":"N Aboul-Fettouh","year":"2017","unstructured":"Aboul-Fettouh N, Hinojosa J, Tovar-Garza A, Pandya AG (2017) The majority of patients presenting with vitiligo have a clinical sign of activity. J Am Acad Dermatol 77(4):774\u2013775. https:\/\/doi.org\/10.1016\/j.jaad.2017.05.027","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"8868_CR56","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/bjd.18950","volume":"183","author":"N van Geel","year":"2020","unstructured":"van Geel N, Passeron T, Wolkerstorfer A, Speeckaert R, Ezzedine K (2020) Reliability and validity of the Vitiligo Signs of Activity Score (VSAS). Br J Dermatol 183(5):883\u2013890. https:\/\/doi.org\/10.1111\/bjd.18950","journal-title":"Br J Dermatol"},{"issue":"5","key":"8868_CR57","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jaad.2017.12.009","volume":"78","author":"AK Jha","year":"2018","unstructured":"Jha AK, Sonthalia S, Lallas A (2018) Dermoscopy as an evolving tool to assess vitiligo activity. J Am Acad Dermatol 78(5):1017\u20131019. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.009","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"8868_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/ijd.13795","volume":"57","author":"A Kumar Jha","year":"2018","unstructured":"Kumar Jha A, Sonthalia S, Lallas A, Chaudhary RKP (2018) Dermoscopy in vitiligo: diagnosis and beyond. Int J Dermatol 57(1):50\u201354. https:\/\/doi.org\/10.1111\/ijd.13795","journal-title":"Int J Dermatol"},{"issue":"5","key":"8868_CR59","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/ced.14151","volume":"45","author":"S Vaccari","year":"2020","unstructured":"Vaccari S, Barisani A, Lacava R, D\u2019Antuono A, Gaspari V, Gurioli C, Patrizi A (2020) Genital vitiligo with reticular pigmentation in a male patient. Clin Exp Dermatol 45(5):590\u2013591. https:\/\/doi.org\/10.1111\/ced.14151","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"8868_CR60","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bjd.13160","volume":"172","author":"L Benzekri","year":"2015","unstructured":"Benzekri L, Hmamouchi I, Gauthier Y (2015) Possible patterns of epidermal melanocyte disappearance in nonsegmental vitiligo: a clinicopathological study. Br J Dermatol 172(2):331\u2013336. https:\/\/doi.org\/10.1111\/bjd.13160","journal-title":"Br J Dermatol"},{"issue":"9","key":"8868_CR61","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.autrev.2017.07.005","volume":"16","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert R, Speeckaert M, De Schepper S, van Geel N (2017) Biomarkers of disease activity in vitiligo: a systematic review. Autoimmun Rev 16(9):937\u2013945. https:\/\/doi.org\/10.1016\/j.autrev.2017.07.005","journal-title":"Autoimmun Rev"},{"issue":"4","key":"8868_CR62","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/ijd.1993.32.4.269","volume":"32","author":"E Galadari","year":"1993","unstructured":"Galadari E, Mehregan AH, Hashimoto K (1993) Ultrastructural study of vitiligo. Int J Dermatol 32(4):269\u2013271. https:\/\/doi.org\/10.1111\/ijd.1993.32.4.269","journal-title":"Int J Dermatol"},{"key":"8868_CR63","doi-asserted-by":"publisher","unstructured":"Boukhedouni N, Martins C, Darrigade AS, Drullion C, Rambert J, Barrault C, Garnier J, Jacquemin C, Thiolat D, Lucchese F, Morel F, Ezzedine K, Taieb A, Bernard FX, Seneschal J, Boniface K (2020) Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight 5 (11). https:\/\/doi.org\/10.1172\/jci.insight.133772","DOI":"10.1172\/jci.insight.133772"},{"issue":"8","key":"8868_CR64","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/DAD.0000000000000539","volume":"38","author":"AK Yadav","year":"2016","unstructured":"Yadav AK, Singh P, Khunger N (2016) Clinicopathologic analysis of stable and unstable vitiligo: a study of 66 cases. Am J Dermatopathol 38(8):608\u2013613. https:\/\/doi.org\/10.1097\/DAD.0000000000000539","journal-title":"Am J Dermatopathol"},{"key":"8868_CR65","doi-asserted-by":"publisher","unstructured":"Saleem MD, Oussedik E, Picardo M, Schoch JJ (2019) Acquired disorders with hypopigmentation: a clinical approach to diagnosis and treatment. J Am Acad Dermatol 80 (5):1233\u20131250 e1210. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.070","DOI":"10.1016\/j.jaad.2018.07.070"},{"issue":"6","key":"8868_CR66","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/pcmr.12814","volume":"32","author":"JM Bae","year":"2019","unstructured":"Bae JM, Eun SH, Kim YH, Park JH, Hann SK (2019) Excimer stamp test distinguishing between nevus depigmentosus and segmental vitiligo. Pigment Cell Melanoma Res 32(6):864\u2013865. https:\/\/doi.org\/10.1111\/pcmr.12814","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"8868_CR67","doi-asserted-by":"publisher","first-page":"7916","DOI":"10.4081\/dr.2018.7916","volume":"11","author":"K Al-Refu","year":"2019","unstructured":"Al-Refu K (2019) Dermoscopy is a new diagnostic tool in diagnosis of common hypopigmented macular disease: a descriptive study. Dermatol Reports 11(1):7916. https:\/\/doi.org\/10.4081\/dr.2018.7916","journal-title":"Dermatol Reports"},{"issue":"4","key":"8868_CR68","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2133.2010.10154.x","volume":"164","author":"N van Geel","year":"2011","unstructured":"van Geel N, Vandenhaute S, Speeckaert R, Brochez L, Mollet I, De Cooman L, Lambert J (2011) Prognostic value and clinical significance of halo naevi regarding vitiligo. Br J Dermatol 164(4):743\u2013749. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10154.x","journal-title":"Br J Dermatol"},{"issue":"4","key":"8868_CR69","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/archdermatol.2011.351","volume":"148","author":"K Ezzedine","year":"2012","unstructured":"Ezzedine K, Diallo A, Leaute-Labreze C, Seneschal J, Mossalayi D, AlGhamdi K, Prey S, Bouchtnei S, Cario-Andre M, Boralevi F, Jouary T, Taieb A (2012) Halo nevi association in nonsegmental vitiligo affects age at onset and depigmentation pattern. Arch Dermatol 148(4):497\u2013502. https:\/\/doi.org\/10.1001\/archdermatol.2011.351","journal-title":"Arch Dermatol"},{"issue":"1","key":"8868_CR70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","volume":"168","author":"A Taieb","year":"2013","unstructured":"Taieb A, Alomar A, Bohm M, Dell\u2019anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M, Vitiligo European Task F, European Academy of D, Venereology, Union Europe enne des Me decins Spe c, (2013) Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 168(1):5\u201319. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11197.x","journal-title":"Br J Dermatol"},{"issue":"5","key":"8868_CR71","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40257-020-00524-0","volume":"21","author":"BE Cohen","year":"2020","unstructured":"Cohen BE, Manga P, Lin K, Elbuluk N (2020) Vitiligo and melanoma-associated vitiligo: understanding their similarities and differences. Am J Clin Dermatol 21(5):669\u2013680. https:\/\/doi.org\/10.1007\/s40257-020-00524-0","journal-title":"Am J Clin Dermatol"},{"key":"8868_CR72","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.lungcan.2017.04.019","volume":"109","author":"T Uenami","year":"2017","unstructured":"Uenami T, Hosono Y, Ishijima M, Kanazu M, Akazawa Y, Yano Y, Mori M, Yamaguchi T, Yokota S (2017) Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report. Lung Cancer 109:42\u201344. https:\/\/doi.org\/10.1016\/j.lungcan.2017.04.019","journal-title":"Lung Cancer"},{"issue":"3","key":"8868_CR73","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","volume":"82","author":"C Nardin","year":"2020","unstructured":"Nardin C, Jeand\u2019heur A, Bouiller K, Valnet-Rabier MB, Dresco F, Castagna J, Mareschal A, Carlet C, Nerich V, Limat S, Puzenat E, Aubin F (2020) Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients. J Am Acad Dermatol 82(3):770\u2013772. https:\/\/doi.org\/10.1016\/j.jaad.2019.11.017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"8868_CR74","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","volume":"76","author":"M Larsabal","year":"2017","unstructured":"Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, Taieb A, Dutriaux C, Prey S, Boniface K, Seneschal J (2017) Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol 76(5):863\u2013870. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.044","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"8868_CR75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","volume":"20","author":"A Taieb","year":"2007","unstructured":"Taieb A, Picardo M, Members V (2007) The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 20(1):27\u201335. https:\/\/doi.org\/10.1111\/j.1600-0749.2006.00355.x","journal-title":"Pigment Cell Res"},{"issue":"5","key":"8868_CR76","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1365-2133.2008.08881.x","volume":"159","author":"Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, Anstey AV, Ingham J, Young K, Therapy G, Audit Subcommittee BAoD, Clinical Standards Department RCoPoL, Cochrane Skin G, Vitiligo S","year":"2008","unstructured":"Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, Anstey AV, Ingham J, Young K, Therapy G, Audit Subcommittee BAoD, Clinical Standards Department RCoPoL, Cochrane Skin G, Vitiligo S (2008) Guideline for the diagnosis and management of vitiligo. Br J Dermatol 159(5):1051\u20131076. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08881.x","journal-title":"Br J Dermatol"},{"key":"8868_CR77","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13311","author":"RM Mogawer","year":"2020","unstructured":"Mogawer RM, Mostafa WZ, Elmasry MF (2020) Comparative analysis of the body surface area calculation method used in vitiligo extent score vs the hand unit method used in vitiligo area severity index. J Cosmet Dermatol. https:\/\/doi.org\/10.1111\/jocd.13311","journal-title":"J Cosmet Dermatol"},{"key":"8868_CR78","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13462","author":"AY Badran","year":"2020","unstructured":"Badran AY, Gomaa AS, El-Mahdy RI, El Zohne RA, Kamal DT, Abou-Taleb DAE (2020) Serum level of S100B in vitiligo patients: is it a marker of disease activity? Australas J Dermatol. https:\/\/doi.org\/10.1111\/ajd.13462","journal-title":"Australas J Dermatol"},{"issue":"10244","key":"8868_CR79","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, Howell MD, Harris JE (2020) Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet 396(10244):110\u2013120. https:\/\/doi.org\/10.1016\/S0140-6736(20)30609-7","journal-title":"Lancet"},{"key":"8868_CR80","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16562","author":"N van Geel","year":"2020","unstructured":"van Geel N, Uitentuis SE, Zuidgeest M, Wolkerstorfer A, Bekkenk MW, Moock C, Van Goethem C, Verlaeckt E, Smet C, Grine L, Speeckaert R (2020) Validation of a Patient Global Assessment for extent, severity and impact to define the severity strata for the Self Assessment Vitiligo Extent Score (SA-VES). J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.16562","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"8868_CR81","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaad.2016.09.034","volume":"76","author":"N van Geel","year":"2017","unstructured":"van Geel N, Lommerts JE, Bekkenk MW, Prinsen CA, Eleftheriadou V, Taieb A, Picardo M, Ezzedine K, Wolkerstorfer A, Speeckaert R, international Vitiligo Score Working G, (2017) Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES). J Am Acad Dermatol 76(3):464\u2013471. https:\/\/doi.org\/10.1016\/j.jaad.2016.09.034","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"8868_CR82","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1111\/jdv.13161","volume":"29","author":"L Komen","year":"2015","unstructured":"Komen L, van der Kraaij GE, van der Veen JP, de Rie MA, Wolkerstorfer A (2015) The validity, reliability and acceptability of the SAVASI; a new self-assessment score in vitiligo. J Eur Acad Dermatol Venereol 29(11):2145\u20132151. https:\/\/doi.org\/10.1111\/jdv.13161","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"8868_CR83","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/pcmr.12784","volume":"32","author":"van Geel N, Wolkerstorfer A, Ezzedine K, Pandya AG, Bekkenk M, Grine L, Van Belle S, Lommerts JE, Hamzavi I, Harris JE, Eleftheriadou V, Esmat S, Kang HY, Kumarasinghe P, Lan CE, Parsad D, Raboobee N, Flora Xiang L, Suzuki T, Prinsen CA, Taieb A, Picardo M, Speeckaert R, participants of the Rome International VVISW","year":"2019","unstructured":"van Geel N, Wolkerstorfer A, Ezzedine K, Pandya AG, Bekkenk M, Grine L, Van Belle S, Lommerts JE, Hamzavi I, Harris JE, Eleftheriadou V, Esmat S, Kang HY, Kumarasinghe P, Lan CE, Parsad D, Raboobee N, Flora Xiang L, Suzuki T, Prinsen CA, Taieb A, Picardo M, Speeckaert R, participants of the Rome International VVISW (2019) Validation of a physician global assessment tool for vitiligo extent: results of an international vitiligo expert meeting. Pigment Cell Melanoma Res 32(5):728\u2013733. https:\/\/doi.org\/10.1111\/pcmr.12784","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"8868_CR84","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/bjd.17013","volume":"180","author":"V Eleftheriadou","year":"2019","unstructured":"Eleftheriadou V, Hamzavi I, Pandya AG, Grimes P, Harris JE, Huggins RH, Lim HW, Elbuluk N, Bhatia B, Tovar-Garza A, Nahhas AF, Braunberger T, Ezzedine K (2019) International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation. Br J Dermatol 180(3):574\u2013579. https:\/\/doi.org\/10.1111\/bjd.17013","journal-title":"Br J Dermatol"},{"issue":"6","key":"8868_CR85","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jaad.2019.10.055","volume":"83","author":"N van Geel","year":"2020","unstructured":"van Geel N, Hamzavi I, Kohli I, Wolkerstorfer A, Lim HW, Bae JM, Lui H, Harris JE, Pandya AG, Thng Tien Guan S, Abdallah M, Esmat S, Seneschal J, Speeckaert R, Grine L, Kang HY, Raboobee N, Xiang LF, Bekkenk M, Picardo M, Taieb A (2020) Standardizing serial photography for assessing and monitoring vitiligo: a core set of international recommendations for essential clinical and technical specifications. J Am Acad Dermatol 83(6):1639\u20131646. https:\/\/doi.org\/10.1016\/j.jaad.2019.10.055","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"8868_CR86","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1684\/ejd.2018.3449","volume":"28","author":"KC Fan","year":"2018","unstructured":"Fan KC, Yang TH, Huang YC (2018) Vitiligo and thyroid disease: a systematic review and meta-analysis. Eur J Dermatol 28(6):750\u2013763. https:\/\/doi.org\/10.1684\/ejd.2018.3449","journal-title":"Eur J Dermatol"},{"key":"8868_CR87","doi-asserted-by":"publisher","unstructured":"Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE (2017) Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol 76 (5):847\u2013855 e845. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.021","DOI":"10.1016\/j.jaad.2016.12.021"},{"issue":"4","key":"8868_CR88","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjd.12691","volume":"170","author":"J Marie","year":"2014","unstructured":"Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B, Picardo M, Taieb A, Ezzedine K, Cario-Andre M (2014) Inflammasome activation and vitiligo\/nonsegmental vitiligo progression. Br J Dermatol 170(4):816\u2013823. https:\/\/doi.org\/10.1111\/bjd.12691","journal-title":"Br J Dermatol"},{"key":"8868_CR89","doi-asserted-by":"publisher","unstructured":"Tsai TY, Kuo CY, Huang YC (2019) Serum homocysteine, folate, and vitamin B12 levels in patients with vitiligo and their potential roles as disease activity biomarkers: a systematic review and meta-analysis. J Am Acad Dermatol 80 (3):646\u2013654 e645. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.029","DOI":"10.1016\/j.jaad.2018.08.029"},{"issue":"2","key":"8868_CR90","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jcla.20442","volume":"25","author":"S Singh","year":"2011","unstructured":"Singh S, Singh U, Pandey SS (2011) Increased level of serum homocysteine in vitiligo. J Clin Lab Anal 25(2):110\u2013112. https:\/\/doi.org\/10.1002\/jcla.20442","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"8868_CR91","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jid.2017.01.033","volume":"137","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert R, Voet S, Hoste E, van Geel N (2017) S100B is a potential disease activity marker in nonsegmental vitiligo. J Invest Dermatol 137(7):1445\u20131453. https:\/\/doi.org\/10.1016\/j.jid.2017.01.033","journal-title":"J Invest Dermatol"},{"issue":"6","key":"8868_CR92","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/exd.13952","volume":"28","author":"A Rahimi","year":"2019","unstructured":"Rahimi A, Hossein-Nataj H, Hajheydari Z, Aryanian Z, Shayannia A, Ajami A, Asgarian-Omran H (2019) Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity. Exp Dermatol 28(6):674\u2013681. https:\/\/doi.org\/10.1111\/exd.13952","journal-title":"Exp Dermatol"},{"issue":"2","key":"8868_CR93","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jdermsci.2018.12.005","volume":"93","author":"L Zhang","year":"2019","unstructured":"Zhang L, Kang Y, Chen S, Wang L, Jiang M, Xiang L (2019) Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1\/17 cells. J Dermatol Sci 93(2):92\u2013100. https:\/\/doi.org\/10.1016\/j.jdermsci.2018.12.005","journal-title":"J Dermatol Sci"},{"key":"8868_CR94","doi-asserted-by":"publisher","first-page":"6879412","DOI":"10.1155\/2019\/6879412","volume":"2019","author":"NS Sawant","year":"2019","unstructured":"Sawant NS, Vanjari NA, Khopkar U (2019) Gender differences in depression, coping, stigma, and quality of life in patients of vitiligo. Dermatol Res Pract 2019:6879412. https:\/\/doi.org\/10.1155\/2019\/6879412","journal-title":"Dermatol Res Pract"},{"issue":"1","key":"8868_CR95","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/JID.2015.398","volume":"136","author":"C Salzes","year":"2016","unstructured":"Salzes C, Abadie S, Seneschal J, Whitton M, Meurant JM, Jouary T, Ballanger F, Boralevi F, Taieb A, Taieb C, Ezzedine K (2016) The vitiligo impact patient scale (vips): development and validation of a vitiligo burden assessment tool. J Invest Dermatol 136(1):52\u201358. https:\/\/doi.org\/10.1038\/JID.2015.398","journal-title":"J Invest Dermatol"},{"issue":"1","key":"8868_CR96","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jaad.2012.01.038","volume":"69","author":"E Lilly","year":"2013","unstructured":"Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, Kundu RV (2013) Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol 69(1):e11-18. https:\/\/doi.org\/10.1016\/j.jaad.2012.01.038","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"8868_CR97","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ajhg.2019.06.013","volume":"105","author":"GHL Roberts","year":"2019","unstructured":"Roberts GHL, Paul S, Yorgov D, Santorico SA, Spritz RA (2019) Family clustering of autoimmune vitiligo results principally from polygenic inheritance of common risk alleles. Am J Hum Genet 105(2):364\u2013372. https:\/\/doi.org\/10.1016\/j.ajhg.2019.06.013","journal-title":"Am J Hum Genet"},{"issue":"3","key":"8868_CR98","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","volume":"16","author":"A Alkhateeb","year":"2003","unstructured":"Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA (2003) Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 16(3):208\u2013214. https:\/\/doi.org\/10.1034\/j.1600-0749.2003.00032.x","journal-title":"Pigment Cell Res"},{"key":"8868_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.06.004","author":"RA Spritz","year":"2020","unstructured":"Spritz RA, Santorico SA (2020) The genetic basis of vitiligo. J Invest Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2020.06.004","journal-title":"J Invest Dermatol"},{"issue":"5","key":"8868_CR100","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/hmg\/ddaa005","volume":"29","author":"GHL Roberts","year":"2020","unstructured":"Roberts GHL, Santorico SA, Spritz RA (2020) Deep genotype imputation captures virtually all heritability of autoimmune vitiligo. Hum Mol Genet 29(5):859\u2013863. https:\/\/doi.org\/10.1093\/hmg\/ddaa005","journal-title":"Hum Mol Genet"},{"issue":"2","key":"8868_CR101","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","volume":"35","author":"RA Spritz","year":"2017","unstructured":"Spritz RA, Andersen GH (2017) Genetics of vitiligo. Dermatol Clin 35(2):245\u2013255. https:\/\/doi.org\/10.1016\/j.det.2016.11.013","journal-title":"Dermatol Clin"},{"issue":"Suppl","key":"8868_CR102","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaut.2005.10.001","volume":"25","author":"T Passeron","year":"2005","unstructured":"Passeron T, Ortonne JP (2005) Physiopathology and genetics of vitiligo. J Autoimmun 25(Suppl):63\u201368. https:\/\/doi.org\/10.1016\/j.jaut.2005.10.001","journal-title":"J Autoimmun"},{"key":"8868_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2015.05.001","volume":"61","author":"CA Yang","year":"2015","unstructured":"Yang CA, Chiang BL (2015) Inflammasomes and human autoimmunity: a comprehensive review. J Autoimmun 61:1\u20138. https:\/\/doi.org\/10.1016\/j.jaut.2015.05.001","journal-title":"J Autoimmun"},{"issue":"4","key":"8868_CR104","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/exd.12641","volume":"24","author":"RG Tarle","year":"2015","unstructured":"Tarle RG, Silva de Castro CC, do Nascimento LM, Mira MT, (2015) Polymorphism of the E-cadherin gene CDH1 is associated with susceptibility to vitiligo. Exp Dermatol 24(4):300\u2013302. https:\/\/doi.org\/10.1111\/exd.12641","journal-title":"Exp Dermatol"},{"key":"8868_CR105","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.gene.2019.03.026","volume":"700","author":"M Almasi-Nasrabadi","year":"2019","unstructured":"Almasi-Nasrabadi M, Amoli MM, Robati RM, Rajabi F, Ghalamkarpour F, Gauthier Y (2019) CDH1 and DDR1 common variants confer risk to vitiligo and autoimmune comorbidities. Gene 700:17\u201322. https:\/\/doi.org\/10.1016\/j.gene.2019.03.026","journal-title":"Gene"},{"issue":"1","key":"8868_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227909","volume":"15","author":"SW Henning","year":"2020","unstructured":"Henning SW, Jaishankar D, Barse LW, Dellacecca ER, Lancki N, Webb K, Janusek L, Mathews HL, Price RN Jr, Le Poole IC (2020) The relationship between stress and vitiligo: evaluating perceived stress and electronic medical record data. PLoS One 15(1):e0227909. https:\/\/doi.org\/10.1371\/journal.pone.0227909","journal-title":"PLoS ONE"},{"issue":"1","key":"8868_CR107","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/jid.2009.214","volume":"130","author":"V Hariharan","year":"2010","unstructured":"Hariharan V, Klarquist J, Reust MJ, Koshoffer A, McKee MD, Boissy RE, Le Poole IC (2010) Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol 130(1):211\u2013220. https:\/\/doi.org\/10.1038\/jid.2009.214","journal-title":"J Invest Dermatol"},{"issue":"5","key":"8868_CR108","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jaad.2018.11.047","volume":"80","author":"IA Vallerand","year":"2019","unstructured":"Vallerand IA, Lewinson RT, Parsons LM, Hardin J, Haber RM, Lowerison MW, Barnabe C, Patten SB (2019) Vitiligo and major depressive disorder: a bidirectional population-based cohort study. J Am Acad Dermatol 80(5):1371\u20131379. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.047","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"8868_CR109","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.0022-202X.2005.23653.x","volume":"124","author":"TM Kroll","year":"2005","unstructured":"Kroll TM, Bommiasamy H, Boissy RE, Hernandez C, Nickoloff BJ, Mestril R, Caroline Le Poole I (2005) 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol 124(4):798\u2013806. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23653.x","journal-title":"J Invest Dermatol"},{"key":"8868_CR110","doi-asserted-by":"publisher","unstructured":"Wang Y, Li S, Li C (2019) Perspectives of new advances in the pathogenesis of vitiligo: from oxidative stress to autoimmunity. Med Sci Monit 25:1017\u20131023. https:\/\/doi.org\/10.12659\/MSM.914898","DOI":"10.12659\/MSM.914898"},{"issue":"1","key":"8868_CR111","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2015.09.003","volume":"81","author":"H Xie","year":"2016","unstructured":"Xie H, Zhou F, Liu L, Zhu G, Li Q, Li C, Gao T (2016) Vitiligo: how do oxidative stress-induced autoantigens trigger autoimmunity? J Dermatol Sci 81(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jdermsci.2015.09.003","journal-title":"J Dermatol Sci"},{"issue":"6","key":"8868_CR112","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.7150\/thno.30398","volume":"9","author":"X Yi","year":"2019","unstructured":"Yi X, Guo W, Shi Q, Yang Y, Zhang W, Chen X, Kang P, Chen J, Cui T, Ma J, Wang H, Guo S, Chang Y, Liu L, Jian Z, Wang L, Xiao Q, Li S, Gao T, Li C (2019) SIRT3-dependent mitochondrial dynamics remodeling contributes to oxidative stress-induced melanocyte degeneration in vitiligo. Theranostics 9(6):1614\u20131633. https:\/\/doi.org\/10.7150\/thno.30398","journal-title":"Theranostics"},{"key":"8868_CR113","doi-asserted-by":"publisher","first-page":"42394","DOI":"10.1038\/srep42394","volume":"7","author":"Y He","year":"2017","unstructured":"He Y, Li S, Zhang W, Dai W, Cui T, Wang G, Gao T, Li C (2017) Dysregulated autophagy increased melanocyte sensitivity to H2O2-induced oxidative stress in vitiligo. Sci Rep 7:42394. https:\/\/doi.org\/10.1038\/srep42394","journal-title":"Sci Rep"},{"issue":"1","key":"8868_CR114","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/jid.2013.268","volume":"134","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Liu L, Jin L, Yi X, Dang E, Yang Y, Li C, Gao T (2014) Oxidative stress-induced calreticulin expression and translocation: new insights into the destruction of melanocytes. J Invest Dermatol 134(1):183\u2013191. https:\/\/doi.org\/10.1038\/jid.2013.268","journal-title":"J Invest Dermatol"},{"issue":"8","key":"8868_CR115","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1038\/jid.2014.152","volume":"134","author":"Z Jian","year":"2014","unstructured":"Jian Z, Li K, Song P, Zhu G, Zhu L, Cui T, Liu B, Tang L, Wang X, Wang G, Gao T, Li C (2014) Impaired activation of the Nrf2-ARE signaling pathway undermines H2O2-induced oxidative stress response: a possible mechanism for melanocyte degeneration in vitiligo. J Invest Dermatol 134(8):2221\u20132230. https:\/\/doi.org\/10.1038\/jid.2014.152","journal-title":"J Invest Dermatol"},{"issue":"3","key":"8868_CR116","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/1523-1747.ep12480976","volume":"97","author":"RE Boissy","year":"1991","unstructured":"Boissy RE, Liu YY, Medrano EE, Nordlund JJ (1991) Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol 97(3):395\u2013404. https:\/\/doi.org\/10.1111\/1523-1747.ep12480976","journal-title":"J Invest Dermatol"},{"issue":"12","key":"8868_CR117","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1038\/sj.jid.5700340","volume":"126","author":"DR Bickers","year":"2006","unstructured":"Bickers DR, Athar M (2006) Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol 126(12):2565\u20132575. https:\/\/doi.org\/10.1038\/sj.jid.5700340","journal-title":"J Invest Dermatol"},{"issue":"5","key":"8868_CR118","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13025","volume":"32","author":"X Yuan","year":"2019","unstructured":"Yuan X, Meng D, Cao P, Sun L, Pang Y, Li Y, Wang X, Luo Z, Zhang L, Liu G (2019) Identification of pathogenic genes and transcription factors in vitiligo. Dermatol Ther 32(5):e13025. https:\/\/doi.org\/10.1111\/dth.13025","journal-title":"Dermatol Ther"},{"key":"8868_CR119","doi-asserted-by":"publisher","unstructured":"Ahn Y, Seo J, Lee EJ, Kim JY, Park MY, Hwang S, Almurayshid A, Lim BJ, Yu JW, Oh SH (2020) ATP-P2X7-induced inflammasome activation contributes to melanocyte death and CD8+ T-cell trafficking to the skin in vitiligo. J Invest Dermatol 140 (9):1794\u20131804 e1794. https:\/\/doi.org\/10.1016\/j.jid.2019.12.035","DOI":"10.1016\/j.jid.2019.12.035"},{"issue":"2","key":"8868_CR120","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jaci.2019.10.036","volume":"145","author":"S Li","year":"2020","unstructured":"Li S, Kang P, Zhang W, Jian Z, Zhang Q, Yi X, Guo S, Guo W, Shi Q, Li B, He Y, Song P, Liu L, Li K, Wang G, Gao T, Li C (2020) Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo. J Allergy Clin Immunol 145(2):632\u2013645. https:\/\/doi.org\/10.1016\/j.jaci.2019.10.036","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"8868_CR121","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jid.2018.06.186","volume":"138","author":"SW Henning","year":"2018","unstructured":"Henning SW, Fernandez MF, Mahon JP, Duff R, Azarafrooz F, Guevara-Patino JA, Rademaker AW, Salzman AL, Le Poole IC (2018) HSP70iQ435A-encoding DNA repigments vitiligo lesions in sinclair swine. J Invest Dermatol 138(12):2531\u20132539. https:\/\/doi.org\/10.1016\/j.jid.2018.06.186","journal-title":"J Invest Dermatol"},{"issue":"4","key":"8868_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018907","volume":"6","author":"CQ Wang","year":"2011","unstructured":"Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N, Sullivan-Whalen M, Gilleaudeau P, Cohen JA, Krueger JG (2011) Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 6(4):e18907. https:\/\/doi.org\/10.1371\/journal.pone.0018907","journal-title":"PLoS ONE"},{"issue":"4","key":"8868_CR123","first-page":"1219","volume":"148","author":"IC Le Poole","year":"1996","unstructured":"Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK (1996) Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 148(4):1219\u20131228","journal-title":"Am J Pathol"},{"issue":"6","key":"8868_CR124","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/jama.293.6.730","volume":"293","author":"PE Grimes","year":"2005","unstructured":"Grimes PE (2005) New insights and new therapies in vitiligo. JAMA 293(6):730\u2013735. https:\/\/doi.org\/10.1001\/jama.293.6.730","journal-title":"JAMA"},{"issue":"5","key":"8868_CR125","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/01.lab.0000069521.42488.1b","volume":"83","author":"A Wankowicz-Kalinska","year":"2003","unstructured":"Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V, Storkus WJ, Das PK (2003) Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 83(5):683\u2013695. https:\/\/doi.org\/10.1097\/01.lab.0000069521.42488.1b","journal-title":"Lab Invest"},{"issue":"6","key":"8868_CR126","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1046\/j.1523-1747.2001.01363.x","volume":"116","author":"KS Lang","year":"2001","unstructured":"Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B, Knauss-Scherwitz E, Stevanovic S, Rammensee HG, Garbe C (2001) HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA\/MART1. J Invest Dermatol 116(6):891\u2013897. https:\/\/doi.org\/10.1046\/j.1523-1747.2001.01363.x","journal-title":"J Invest Dermatol"},{"issue":"3","key":"8868_CR127","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1046\/j.1523-1747.2003.12413.x","volume":"121","author":"RL Mandelcorn-Monson","year":"2003","unstructured":"Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, DeBenedette MA (2003) Cytotoxic T lymphocyte reactivity to gp100, MelanA\/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 121(3):550\u2013556. https:\/\/doi.org\/10.1046\/j.1523-1747.2003.12413.x","journal-title":"J Invest Dermatol"},{"issue":"6","key":"8868_CR128","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","volume":"188","author":"GS Ogg","year":"1998","unstructured":"Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V (1998) High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188(6):1203\u20131208. https:\/\/doi.org\/10.1084\/jem.188.6.1203","journal-title":"J Exp Med"},{"issue":"2","key":"8868_CR129","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1046\/j.1523-1747.2001.01408.x","volume":"117","author":"B Palermo","year":"2001","unstructured":"Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, Ardigo M, Borroni G, Martinetti M, Badulli C, Necker A, Giachino C (2001) Specific cytotoxic T lymphocyte responses against Melan-A\/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex\/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 117(2):326\u2013332. https:\/\/doi.org\/10.1046\/j.1523-1747.2001.01408.x","journal-title":"J Invest Dermatol"},{"issue":"1","key":"8868_CR130","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/imr.12762","volume":"289","author":"JM Richmond","year":"2019","unstructured":"Richmond JM, Strassner JP, Essien KI, Harris JE (2019) T-cell positioning by chemokines in autoimmune skin diseases. Immunol Rev 289(1):186\u2013204. https:\/\/doi.org\/10.1111\/imr.12762","journal-title":"Immunol Rev"},{"issue":"9","key":"8868_CR131","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA, Luiten RM (2009) Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 129(9):2220\u20132232. https:\/\/doi.org\/10.1038\/jid.2009.32","journal-title":"J Invest Dermatol"},{"issue":"7","key":"8868_CR132","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","volume":"132","author":"JE Harris","year":"2012","unstructured":"Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA (2012) A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol 132(7):1869\u20131876. https:\/\/doi.org\/10.1038\/jid.2011.463","journal-title":"J Invest Dermatol"},{"issue":"1","key":"8868_CR133","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3892\/mmr.2012.1117","volume":"7","author":"J Wu","year":"2013","unstructured":"Wu J, Zhou M, Wan Y, Xu A (2013) CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis. Mol Med Rep 7(1):237\u2013241. https:\/\/doi.org\/10.3892\/mmr.2012.1117","journal-title":"Mol Med Rep"},{"issue":"6","key":"8868_CR134","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.jaci.2018.11.031","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Leonard A, Kim HJ, Kameyama N, Pavel AB, Li R, Estrada Y, Wen HC, Kimmel GW, Kim HJ, Chima M, Lebwohl M, Krueger JG, Guttman-Yassky E (2019) Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. J Allergy Clin Immunol 143(6):2095\u20132107. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.031","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8868_CR135","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jaci.2020.05.009","volume":"146","author":"JE Gudjonsson","year":"2020","unstructured":"Gudjonsson JE, Kabashima K, Eyerich K (2020) Mechanisms of skin autoimmunity: cellular and soluble immune components of the skin. J Allergy Clin Immunol 146(1):8\u201316. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.009","journal-title":"J Allergy Clin Immunol"},{"key":"8868_CR136","doi-asserted-by":"publisher","unstructured":"van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das P (2000) Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 80 (8):1299\u20131309. https:\/\/doi.org\/10.1038\/labinvest.3780138","DOI":"10.1038\/labinvest.3780138"},{"issue":"6","key":"8868_CR137","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1046\/j.0022-202x.2001.01605.x","volume":"117","author":"FA Le Gal","year":"2001","unstructured":"Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG (2001) Direct evidence to support the role of antigen-specific CD8+ T cells in melanoma-associated vitiligo. J Invest Dermatol 117(6):1464\u20131470. https:\/\/doi.org\/10.1046\/j.0022-202x.2001.01605.x","journal-title":"J Invest Dermatol"},{"issue":"8929","key":"8868_CR138","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/s0140-6736(94)91709-4","volume":"344","author":"YH Song","year":"1994","unstructured":"Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N (1994) The role of tyrosinase in autoimmune vitiligo. Lancet 344(8929):1049\u20131052. https:\/\/doi.org\/10.1016\/s0140-6736(94)91709-4","journal-title":"Lancet"},{"issue":"1","key":"8868_CR139","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/1346-8138.14004","volume":"45","author":"L Yang","year":"2018","unstructured":"Yang L, Yang S, Lei J, Hu W, Chen R, Lin F, Xu AE (2018) Role of chemokines and the corresponding receptors in vitiligo: a pilot study. J Dermatol 45(1):31\u201338. https:\/\/doi.org\/10.1111\/1346-8138.14004","journal-title":"J Dermatol"},{"key":"8868_CR140","doi-asserted-by":"publisher","unstructured":"Li S, Zhu G, Yang Y, Jian Z, Guo S, Dai W, Shi Q, Ge R, Ma J, Liu L, Li K, Luan Q, Wang G, Gao T, Li C (2017) Oxidative stress drives CD8+ T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes. J Allergy Clin Immunol 140 (1):177\u2013189 e179. https:\/\/doi.org\/10.1016\/j.jaci.2016.10.013","DOI":"10.1016\/j.jaci.2016.10.013"},{"key":"8868_CR141","doi-asserted-by":"publisher","unstructured":"Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris JE (2014) CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med 6 (223):223ra223. https:\/\/doi.org\/10.1126\/scitranslmed.3007811","DOI":"10.1126\/scitranslmed.3007811"},{"issue":"4","key":"8868_CR142","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jid.2016.10.048","volume":"137","author":"JM Richmond","year":"2017","unstructured":"Richmond JM, Masterjohn E, Chu R, Tedstone J, Youd ME, Harris JE (2017) CXCR3 depleting antibodies prevent and reverse vitiligo in mice. J Invest Dermatol 137(4):982\u2013985. https:\/\/doi.org\/10.1016\/j.jid.2016.10.048","journal-title":"J Invest Dermatol"},{"issue":"3","key":"8868_CR143","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2013.03.002","volume":"38","author":"N Ohkura","year":"2013","unstructured":"Ohkura N, Kitagawa Y, Sakaguchi S (2013) Development and maintenance of regulatory T cells. Immunity 38(3):414\u2013423. https:\/\/doi.org\/10.1016\/j.immuni.2013.03.002","journal-title":"Immunity"},{"issue":"8","key":"8868_CR144","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/exd.14157","volume":"29","author":"PS Giri","year":"2020","unstructured":"Giri PS, Dwivedi M, Begum R (2020) Decreased suppression of CD8+ and CD4+ T cells by peripheral regulatory T cells in generalized vitiligo due to reduced NFATC1 and FOXP3 proteins. Exp Dermatol 29(8):759\u2013775. https:\/\/doi.org\/10.1111\/exd.14157","journal-title":"Exp Dermatol"},{"issue":"4","key":"8868_CR145","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/pcmr.12862","volume":"33","author":"PS Giri","year":"2020","unstructured":"Giri PS, Dwivedi M, Laddha NC, Begum R, Bharti AH (2020) Altered expression of nuclear factor of activated T cells, forkhead box P3, and immune-suppressive genes in regulatory T cells of generalized vitiligo patients. Pigment Cell Melanoma Res 33(4):566\u2013578. https:\/\/doi.org\/10.1111\/pcmr.12862","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"8868_CR146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037513","volume":"7","author":"Y Lili","year":"2012","unstructured":"Lili Y, Yi W, Ji Y, Yue S, Weimin S, Ming L (2012) Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 7(5):e37513. https:\/\/doi.org\/10.1371\/journal.pone.0037513","journal-title":"PLoS ONE"},{"issue":"5","key":"8868_CR147","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/jid.2013.540","volume":"134","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee S, Eby JM, Al-Khami AA, Soloshchenko M, Kang HK, Kaur N, Naga OS, Murali A, Nishimura MI, Caroline Le Poole I, Mehrotra S (2014) A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol 134(5):1285\u20131294. https:\/\/doi.org\/10.1038\/jid.2013.540","journal-title":"J Invest Dermatol"},{"issue":"4","key":"8868_CR148","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.4049\/jimmunol.0902778","volume":"184","author":"RK Gregg","year":"2010","unstructured":"Gregg RK, Nichols L, Chen Y, Lu B, Engelhard VH (2010) Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol 184(4):1909\u20131917. https:\/\/doi.org\/10.4049\/jimmunol.0902778","journal-title":"J Immunol"},{"issue":"2","key":"8868_CR149","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","volume":"23","author":"J Klarquist","year":"2010","unstructured":"Klarquist J, Denman CJ, Hernandez C, Wainwright DA, Strickland FM, Overbeck A, Mehrotra S, Nishimura MI, Le Poole IC (2010) Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 23(2):276\u2013286. https:\/\/doi.org\/10.1111\/j.1755-148X.2010.00688.x","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"8868_CR150","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/jid.2015.26","volume":"135","author":"JM Eby","year":"2015","unstructured":"Eby JM, Kang HK, Tully ST, Bindeman WE, Peiffer DS, Chatterjee S, Mehrotra S, Le Poole IC (2015) CCL22 to activate Treg migration and suppress depigmentation in vitiligo. J Invest Dermatol 135(6):1574\u20131580. https:\/\/doi.org\/10.1038\/jid.2015.26","journal-title":"J Invest Dermatol"},{"issue":"2","key":"8868_CR151","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jisp.2016.10.023","volume":"18","author":"IC Le Poole","year":"2017","unstructured":"Le Poole IC, Mehrotra S (2017) Replenishing regulatory T cells to halt depigmentation in vitiligo. J Investig Dermatol Symp Proc 18(2):S38\u2013S45. https:\/\/doi.org\/10.1016\/j.jisp.2016.10.023","journal-title":"J Investig Dermatol Symp Proc"},{"key":"8868_CR152","doi-asserted-by":"publisher","unstructured":"Richmond JM, Strassner JP, Zapata L, Jr., Garg M, Riding RL, Refat MA, Fan X, Azzolino V, Tovar-Garza A, Tsurushita N, Pandya AG, Tso JY, Harris JE (2018) Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med 10 (450). https:\/\/doi.org\/10.1126\/scitranslmed.aam7710","DOI":"10.1126\/scitranslmed.aam7710"},{"issue":"2","key":"8868_CR153","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","volume":"138","author":"K Boniface","year":"2018","unstructured":"Boniface K, Jacquemin C, Darrigade AS, Dessarthe B, Martins C, Boukhedouni N, Vernisse C, Grasseau A, Thiolat D, Rambert J, Lucchese F, Bertolotti A, Ezzedine K, Taieb A, Seneschal J (2018) Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3. J Invest Dermatol 138(2):355\u2013364. https:\/\/doi.org\/10.1016\/j.jid.2017.08.038","journal-title":"J Invest Dermatol"},{"issue":"2","key":"8868_CR154","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","volume":"46","author":"S Cheuk","year":"2017","unstructured":"Cheuk S, Schlums H, Gallais Serezal I, Martini E, Chiang SC, Marquardt N, Gibbs A, Detlofsson E, Introini A, Forkel M, Hoog C, Tjernlund A, Michaelsson J, Folkersen L, Mjosberg J, Blomqvist L, Ehrstrom M, Stahle M, Bryceson YT, Eidsmo L (2017) CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin. Immunity 46(2):287\u2013300. https:\/\/doi.org\/10.1016\/j.immuni.2017.01.009","journal-title":"Immunity"},{"issue":"4","key":"8868_CR155","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jid.2018.10.032","volume":"139","author":"JM Richmond","year":"2019","unstructured":"Richmond JM, Strassner JP, Rashighi M, Agarwal P, Garg M, Essien KI, Pell LS, Harris JE (2019) Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo. J Invest Dermatol 139(4):769\u2013778. https:\/\/doi.org\/10.1016\/j.jid.2018.10.032","journal-title":"J Invest Dermatol"},{"key":"8868_CR156","doi-asserted-by":"publisher","unstructured":"Jacquemin C, Martins C, Lucchese F, Thiolat D, Taieb A, Seneschal J, Boniface K (2020) NKG2D defines a subset of skin effector memory CD8 T cells with proinflammatory functions in vitiligo. J Invest Dermatol 140 (6):1143\u20131153 e1145. https:\/\/doi.org\/10.1016\/j.jid.2019.11.013","DOI":"10.1016\/j.jid.2019.11.013"},{"key":"8868_CR157","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2019.05.011","volume":"139","author":"X Chen","year":"2019","unstructured":"Chen X, Guo W, Chang Y, Chen J, Kang P, Yi X, Cui T, Guo S, Xiao Q, Jian Z, Li K, Gao T, Li S, Liu L, Li C (2019) Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8+ T cells activation via JAK-STAT pathway in vitiligo. Free Radic Biol Med 139:80\u201391. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2019.05.011","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"8868_CR158","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/bjd.15550","volume":"177","author":"C Jacquemin","year":"2017","unstructured":"Jacquemin C, Rambert J, Guillet S, Thiolat D, Boukhedouni N, Doutre MS, Darrigade AS, Ezzedine K, Blanco P, Taieb A, Boniface K, Seneschal J (2017) Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. Br J Dermatol 177(5):1367\u20131375. https:\/\/doi.org\/10.1111\/bjd.15550","journal-title":"Br J Dermatol"},{"issue":"9","key":"8868_CR159","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41577-020-0282-9","volume":"20","author":"SM Bal","year":"2020","unstructured":"Bal SM, Golebski K, Spits H (2020) Plasticity of innate lymphoid cell subsets. Nat Rev Immunol 20(9):552\u2013565. https:\/\/doi.org\/10.1038\/s41577-020-0282-9","journal-title":"Nat Rev Immunol"},{"key":"8868_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0426-7","author":"JA Myers","year":"2020","unstructured":"Myers JA, Miller JS (2020) Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/s41571-020-0426-7","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"8868_CR161","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.immuni.2016.05.008","volume":"44","author":"JG van den Boorn","year":"2016","unstructured":"van den Boorn JG, Jakobs C, Hagen C, Renn M, Luiten RM, Melief CJ, Tuting T, Garbi N, Hartmann G, Hornung V (2016) Inflammasome-dependent induction of adaptive NK cell memory. Immunity 44(6):1406\u20131421. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.008","journal-title":"Immunity"},{"issue":"12","key":"8868_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051040","volume":"7","author":"R Yu","year":"2012","unstructured":"Yu R, Broady R, Huang Y, Wang Y, Yu J, Gao M, Levings M, Wei S, Zhang S, Xu A, Su M, Dutz J, Zhang X, Zhou Y (2012) Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLoS One 7(12):e51040. https:\/\/doi.org\/10.1371\/journal.pone.0051040","journal-title":"PLoS ONE"},{"issue":"5 Pt 1","key":"8868_CR163","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/s0190-9622(86)70085-6","volume":"14","author":"RM Halder","year":"1986","unstructured":"Halder RM, Walters CS, Johnson BA, Chakrabarti SG, Kenney JA Jr (1986) Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study. J Am Acad Dermatol 14(5 Pt 1):733\u2013737. https:\/\/doi.org\/10.1016\/s0190-9622(86)70085-6","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"8868_CR164","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","volume":"137","author":"JM Richmond","year":"2017","unstructured":"Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG, Youd ME, Luster AD, Harris JE (2017) Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol 137(2):350\u2013358. https:\/\/doi.org\/10.1016\/j.jid.2016.09.016","journal-title":"J Invest Dermatol"},{"issue":"2","key":"8868_CR165","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.det.2016.11.002","volume":"35","author":"N Elbuluk","year":"2017","unstructured":"Elbuluk N, Ezzedine K (2017) Quality of Life, Burden of Disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin 35(2):117\u2013128. https:\/\/doi.org\/10.1016\/j.det.2016.11.002","journal-title":"Dermatol Clin"},{"issue":"2","key":"8868_CR166","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","volume":"74","author":"L Gill","year":"2016","unstructured":"Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I (2016) Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol 74(2):295\u2013302. https:\/\/doi.org\/10.1016\/j.jaad.2015.08.063","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"8868_CR167","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/ijd.14055","volume":"57","author":"AM Dahir","year":"2018","unstructured":"Dahir AM, Thomsen SF (2018) Comorbidities in vitiligo: comprehensive review. Int J Dermatol 57(10):1157\u20131164. https:\/\/doi.org\/10.1111\/ijd.14055","journal-title":"Int J Dermatol"},{"issue":"6","key":"8868_CR168","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jaad.2019.06.022","volume":"81","author":"HC Chang","year":"2019","unstructured":"Chang HC, Lin MH, Huang YC, Hou TY (2019) The association between vitiligo and diabetes mellitus: a systematic review and meta-analysis. J Am Acad Dermatol 81(6):1442\u20131445. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"8868_CR169","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/bjd.13276","volume":"172","author":"TS Anbar","year":"2015","unstructured":"Anbar TS, El-Badry MM, McGrath JA, Abdel-Azim ES (2015) Most individuals with either segmental or non-segmental vitiligo display evidence of bilateral cochlear dysfunction. Br J Dermatol 172(2):406\u2013411. https:\/\/doi.org\/10.1111\/bjd.13276","journal-title":"Br J Dermatol"},{"issue":"3","key":"8868_CR170","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4274\/balkanmedj.2016.1005","volume":"34","author":"H Atas","year":"2017","unstructured":"Atas H, Gonul M (2017) Increased risk of metabolic syndrome in patients with vitiligo. Balkan Med J 34(3):219\u2013225. https:\/\/doi.org\/10.4274\/balkanmedj.2016.1005","journal-title":"Balkan Med J"},{"issue":"1","key":"8868_CR171","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12016-019-08756-7","volume":"58","author":"DD Odineal","year":"2020","unstructured":"Odineal DD, Gershwin ME (2020) The epidemiology and clinical manifestations of autoimmunity in selective IgA deficiency. Clin Rev Allergy Immunol 58(1):107\u2013133. https:\/\/doi.org\/10.1007\/s12016-019-08756-7","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"8868_CR172","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jdcr.2020.06.039","volume":"6","author":"K Saleh","year":"2020","unstructured":"Saleh K (2020) Prurigo nodularis in vitiligo patches: an unusual observation. JAAD Case Rep 6(9):841\u2013842. https:\/\/doi.org\/10.1016\/j.jdcr.2020.06.039","journal-title":"JAAD Case Rep"},{"issue":"3","key":"8868_CR173","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jaad.2019.07.029","volume":"82","author":"S Narla","year":"2020","unstructured":"Narla S, Silverberg JI (2020) Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients. J Am Acad Dermatol 82(3):586\u2013595. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.029","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"8868_CR174","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1200\/JCO.18.01223","volume":"37","author":"JM Bae","year":"2019","unstructured":"Bae JM, Chung KY, Yun SJ, Kim H, Park BC, Kim JS, Seo SH, Ahn HH, Lee DY, Kim YC, Park HJ, Kim M (2019) Markedly reduced risk of internal malignancies in patients with vitiligo: a nationwide population-based cohort study. J Clin Oncol 37(11):903\u2013911. https:\/\/doi.org\/10.1200\/JCO.18.01223","journal-title":"J Clin Oncol"},{"issue":"4","key":"8868_CR175","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/bjd.16703","volume":"179","author":"L Ban","year":"2018","unstructured":"Ban L, Labbouz S, Grindlay D, Batchelor JM, Ratib S (2018) Risk of skin cancer in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol 179(4):971\u2013972. https:\/\/doi.org\/10.1111\/bjd.16703","journal-title":"Br J Dermatol"},{"issue":"1","key":"8868_CR176","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.det.2019.08.005","volume":"38","author":"R Zubair","year":"2020","unstructured":"Zubair R, Hamzavi IH (2020) Phototherapy for vitiligo. Dermatol Clin 38(1):55\u201362. https:\/\/doi.org\/10.1016\/j.det.2019.08.005","journal-title":"Dermatol Clin"},{"key":"8868_CR177","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0696","author":"JH Lee","year":"2019","unstructured":"Lee JH, Kwon HS, Jung HM, Lee H, Kim GM, Yim HW, Bae JM (2019) Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol 155(8):929-938.\u00a0https:\/\/doi.org\/10.1001\/jamadermatol.2019.0696","journal-title":"JAMA Dermatol"},{"key":"8868_CR178","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19592","author":"Thomas KS, Batchelor JM, Akram P, Chalmers JR, Haines RH, Meakin GD, Duley L, Ravenscroft JC, Rogers A, Sach TH, Santer M, Tan W, White J, Whitton ME, Williams HC, Cheung ST, Hamad H, Wright A, Ingram JR, Levell NJ, Goulding JMR, Makrygeorgou A, Bewley A, Ogboli M, Stainforth J, Ferguson A, Laguda B, Wahie S, Ellis R, Azad J, Rajasekaran A, Eleftheriadou V, Montgomery AA, Team UKDCTNsH-LVT","year":"2020","unstructured":"Thomas KS, Batchelor JM, Akram P, Chalmers JR, Haines RH, Meakin GD, Duley L, Ravenscroft JC, Rogers A, Sach TH, Santer M, Tan W, White J, Whitton ME, Williams HC, Cheung ST, Hamad H, Wright A, Ingram JR, Levell NJ, Goulding JMR, Makrygeorgou A, Bewley A, Ogboli M, Stainforth J, Ferguson A, Laguda B, Wahie S, Ellis R, Azad J, Rajasekaran A, Eleftheriadou V, Montgomery AA, Team UKDCTNsH-LVT (2020) Randomised controlled trial of topical corticosteroid and home-based narrowband UVB for active and limited vitiligo - results of the HI-Light vitiligo trial. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.19592","journal-title":"Br J Dermatol"},{"issue":"2","key":"8868_CR179","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.det.2016.11.007","volume":"35","author":"T Passeron","year":"2017","unstructured":"Passeron T (2017) Medical and maintenance treatments for vitiligo. Dermatol Clin 35(2):163\u2013170. https:\/\/doi.org\/10.1016\/j.det.2016.11.007","journal-title":"Dermatol Clin"},{"issue":"1","key":"8868_CR180","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/jocd.13459","volume":"20","author":"D Bassiouny","year":"2021","unstructured":"Bassiouny D, Hegazy R, Esmat S, Gawdat HI, Ahmed Ezzat M, Tawfik HA, Hegazy AA, Ibrahim S (2021) Cosmetic camouflage as an adjuvant to vitiligo therapies: Effect on quality of life. J Cosmet Dermatol 20(1):159\u2013165. https:\/\/doi.org\/10.1111\/jocd.13459","journal-title":"J Cosmet Dermatol"},{"issue":"3","key":"8868_CR181","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamadermatol.2020.5756","volume":"157","author":"HJ Ju","year":"2021","unstructured":"Ju HJ, Bae JM, Lee RW, Kim SH, Parsad D, Pourang A, Hamzavi I, Shourick J, Ezzedine K (2021) Surgical interventions for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol 157(3):307\u2013316. https:\/\/doi.org\/10.1001\/jamadermatol.2020.5756","journal-title":"JAMA Dermatol"},{"key":"8868_CR182","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19630","author":"A Rogers","year":"2020","unstructured":"Rogers A, Akram P, Batchelor JM, Crutchley J, Grocki M, Haines RH, Meakin G, O\u2019Dowd K, Ravenscroft J, Thomas KS (2020) Quality assurance and characterisation of NB-UVB devices for use at home - lessons from the Hi-Light vitiligo trial. Br J Dermatol 184(5):954\u2013955.\u00a0https:\/\/doi.org\/10.1111\/bjd.19630","journal-title":"Br J Dermatol"},{"key":"8868_CR183","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16927","author":"VS Narayan","year":"2020","unstructured":"Narayan VS, Uitentuis SE, Luiten RM, Bekkenk MW, Wolkerstorfer A (2020) Patients\u2019 perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.16927","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"8868_CR184","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.det.2016.11.014","volume":"35","author":"M Rashighi","year":"2017","unstructured":"Rashighi M, Harris JE (2017) Vitiligo pathogenesis and emerging treatments. Dermatol Clin 35(2):257\u2013265. https:\/\/doi.org\/10.1016\/j.det.2016.11.014","journal-title":"Dermatol Clin"},{"key":"8868_CR185","doi-asserted-by":"publisher","unstructured":"Liu LY, Strassner JP, Refat MA, Harris JE, King BA (2017) Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol 77 (4):675\u2013682 e671. https:\/\/doi.org\/10.1016\/j.jaad.2017.05.043","DOI":"10.1016\/j.jaad.2017.05.043"},{"issue":"3","key":"8868_CR186","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","volume":"154","author":"SR Kim","year":"2018","unstructured":"Kim SR, Heaton H, Liu LY, King BA (2018) Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy. JAMA Dermatol 154(3):370\u2013371. https:\/\/doi.org\/10.1001\/jamadermatol.2017.5778","journal-title":"JAMA Dermatol"},{"key":"8868_CR187","doi-asserted-by":"crossref","unstructured":"Nguyen JK, Schlichte MJ, Jogi R, Alikhan M, Patel AB (2020) A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies. Dermatol Online J 26 (3)","DOI":"10.5070\/D3263047978"},{"key":"8868_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.04.027","author":"V Azzolino","year":"2020","unstructured":"Azzolino V, Zapata L Jr, Garg M, Gjoni M, Riding RL, Strassner JP, Richmond JM, Harris JE (2020) Jak inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells. J Invest Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2020.04.027","journal-title":"J Invest Dermatol"},{"key":"8868_CR189","doi-asserted-by":"publisher","unstructured":"Khemis A, Fontas E, Moulin S, Montaudie H, Lacour JP, Passeron T (2020) Apremilast in combination with narrowband UVB in the treatment of vitiligo: a 52-week monocentric prospective randomized placebo-controlled study. J Invest Dermatol 140 (8):1533\u20131537 e1532. https:\/\/doi.org\/10.1016\/j.jid.2019.11.031","DOI":"10.1016\/j.jid.2019.11.031"},{"issue":"6","key":"8868_CR190","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/pcmr.12789","volume":"32","author":"R Speeckaert","year":"2019","unstructured":"Speeckaert R, Mylle S, van Geel N (2019) IL-17A is not a treatment target in progressive vitiligo. Pigment Cell Melanoma Res 32(6):842\u2013847. https:\/\/doi.org\/10.1111\/pcmr.12789","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"8868_CR191","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s13555-020-00447-y","volume":"10","author":"L Migayron","year":"2020","unstructured":"Migayron L, Boniface K, Seneschal J (2020) Vitiligo, from physiopathology to emerging treatments: a review. Dermatol Ther (Heidelb) 10(6):1185\u20131198. https:\/\/doi.org\/10.1007\/s13555-020-00447-y","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"8868_CR192","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jid.2019.03.1142","volume":"140","author":"CC Barbulescu","year":"2020","unstructured":"Barbulescu CC, Goldstein NB, Roop DR, Norris DA, Birlea SA (2020) Harnessing the power of regenerative therapy for vitiligo and alopecia areata. J Invest Dermatol 140(1):29\u201337. https:\/\/doi.org\/10.1016\/j.jid.2019.03.1142","journal-title":"J Invest Dermatol"},{"issue":"6","key":"8868_CR193","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/pcmr.12878","volume":"33","author":"ZA Abdel-Malek","year":"2020","unstructured":"Abdel-Malek ZA, Jordan C, Ho T, Upadhyay PR, Fleischer A, Hamzavi I (2020) The enigma and challenges of vitiligo pathophysiology and treatment. Pigment Cell Melanoma Res 33(6):778\u2013787. https:\/\/doi.org\/10.1111\/pcmr.12878","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"8868_CR194","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jaad.2020.01.035","volume":"82","author":"JJH Toh","year":"2020","unstructured":"Toh JJH, Chuah SY, Jhingan A, Chong WS, Thng STG (2020) Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians. J Am Acad Dermatol 82(6):1517\u20131519. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.035","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"8868_CR195","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1038\/jid.2015.335","volume":"135","author":"C Regazzetti","year":"2015","unstructured":"Regazzetti C, Joly F, Marty C, Rivier M, Mehul B, Reiniche P, Mounier C, Rival Y, Piwnica D, Cavalie M, Chignon-Sicard B, Ballotti R, Voegel J, Passeron T (2015) Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients. J Invest Dermatol 135(12):3105\u20133114. https:\/\/doi.org\/10.1038\/jid.2015.335","journal-title":"J Invest Dermatol"},{"key":"8868_CR196","doi-asserted-by":"publisher","unstructured":"Cortelazzi C, Pellacani G, Raposio E, Di Nuzzo S (2020) Vitiligo management: combination of surgical treatment and phototherapy under reflectance confocal microscopy monitoring. Eur Rev Med Pharmacol Sci 24 (13):7366\u20137371. https:\/\/doi.org\/10.26355\/eurrev_202007_21904","DOI":"10.26355\/eurrev_202007_21904"},{"issue":"2","key":"8868_CR197","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jaad.2017.12.054","volume":"79","author":"SA Elshafy Khashaba","year":"2018","unstructured":"Elshafy Khashaba SA, Elkot RA, Ibrahim AM (2018) Efficacy of NB-UVB, microneedling with triamcinolone acetonide, and a combination of both modalities in the treatment of vitiligo: a comparative study. J Am Acad Dermatol 79(2):365\u2013367. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.054","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8868_CR198","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jaad.2019.04.037","volume":"81","author":"MJ Hesseler","year":"2019","unstructured":"Hesseler MJ, Shyam N (2019) Platelet-rich plasma and its utility in medical dermatology: a systematic review. J Am Acad Dermatol 81(3):834\u2013846. https:\/\/doi.org\/10.1016\/j.jaad.2019.04.037","journal-title":"J Am Acad Dermatol"},{"key":"8868_CR199","doi-asserted-by":"publisher","unstructured":"Vocetkova K, Sovkova V, Buzgo M, Lukasova V, Divin R, Rampichova M, Blazek P, Zikmund T, Kaiser J, Karpisek Z, Amler E, Filova E (2020) A simple drug delivery system for platelet-derived bioactive molecules, to improve melanocyte stimulation in vitiligo treatment. Nanomaterials (Basel) 10 (9). https:\/\/doi.org\/10.3390\/nano10091801","DOI":"10.3390\/nano10091801"},{"issue":"10244","key":"8868_CR200","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(20)30747-9","volume":"396","author":"T Passeron","year":"2020","unstructured":"Passeron T (2020) First step in a new era for treatment of patients with vitiligo. Lancet 396(10244):74\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(20)30747-9","journal-title":"Lancet"},{"key":"8868_CR201","doi-asserted-by":"publisher","unstructured":"Pacifico A, Damiani G, Iacovelli P, Conic RRZ, Young Dermatologists Italian N, Gonzalez S, Morrone A (2021) NB-UVB plus oral Polypodium leucotomos extract display higher efficacy than NB-UVB alone in patients with vitiligo. Dermatol Ther:e14776. https:\/\/doi.org\/10.1111\/dth.14776","DOI":"10.1111\/dth.14776"},{"issue":"5","key":"8868_CR202","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ccr3.2759","volume":"8","author":"M Tajalli","year":"2020","unstructured":"Tajalli M, Kabir S, Vance TM, Qureshi AA (2020) Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis. Clin Case Rep 8(5):819\u2013822. https:\/\/doi.org\/10.1002\/ccr3.2759","journal-title":"Clin Case Rep"},{"issue":"5","key":"8868_CR203","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jaad.2016.12.041","volume":"76","author":"TF Mohammad","year":"2017","unstructured":"Mohammad TF, Al-Jamal M, Hamzavi IH, Harris JE, Leone G, Cabrera R, Lim HW, Pandya AG, Esmat SM (2017) The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. J Am Acad Dermatol 76(5):879\u2013888. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.041","journal-title":"J Am Acad Dermatol"},{"key":"8868_CR204","doi-asserted-by":"publisher","unstructured":"Wong PM, Yang L, Yang L, Wu H, Li W, Ma X, Katayama I, Zhang H (2020) New insight into the role of exosomes in vitiligo. Autoimmun Rev:102664. https:\/\/doi.org\/10.1016\/j.autrev.2020.102664","DOI":"10.1016\/j.autrev.2020.102664"},{"issue":"20","key":"8868_CR205","doi-asserted-by":"publisher","first-page":"12164","DOI":"10.1111\/jcmm.15864","volume":"24","author":"C Zhao","year":"2020","unstructured":"Zhao C, Wang D, Wang X, Mao Y, Xu Z, Sun Y, Mei X, Song J, Shi W (2020) Down-regulation of exosomal miR-200c derived from keratinocytes in vitiligo lesions suppresses melanogenesis. J Cell Mol Med 24(20):12164\u201312175. https:\/\/doi.org\/10.1111\/jcmm.15864","journal-title":"J Cell Mol Med"},{"key":"8868_CR206","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-020-02117-7","author":"AS Hassan","year":"2020","unstructured":"Hassan AS, Kohil MM, Sayed SSE, Mahmoud SB (2021) Immunohistochemical study of perforin and apoptosis stimulation fragment ligand (FasL) in active vitiligo. Arch Dermatol Res 313(6):453\u2013460. https:\/\/doi.org\/10.1007\/s00403-020-02117-7","journal-title":"Arch Dermatol Res"},{"key":"8868_CR207","doi-asserted-by":"publisher","DOI":"10.1002\/med.21754","author":"J Chen","year":"2020","unstructured":"Chen J, Li S, Li C (2020) Mechanisms of melanocyte death in vitiligo. Med Res Rev 41(2):1138\u20131166.\u00a0https:\/\/doi.org\/10.1002\/med.21754","journal-title":"Med Res Rev"},{"issue":"9","key":"8868_CR208","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239176","volume":"15","author":"O Danielsson","year":"2020","unstructured":"Danielsson O, Haggqvist B, Grontoft L, Ollinger K, Ernerudh J (2020) Apoptosis in idiopathic inflammatory myopathies with partial invasion; a role for CD8+ cytotoxic T cells? PLoS One 15(9):e0239176. https:\/\/doi.org\/10.1371\/journal.pone.0239176","journal-title":"PLoS ONE"},{"issue":"23","key":"8868_CR209","doi-asserted-by":"publisher","first-page":"12961","DOI":"10.1073\/pnas.1914667117","volume":"117","author":"MZ Chaudhry","year":"2020","unstructured":"Chaudhry MZ, Casalegno-Garduno R, Sitnik KM, Kasmapour B, Pulm AK, Brizic I, Eiz-Vesper B, Moosmann A, Jonjic S, Mocarski ES, Cicin-Sain L (2020) Cytomegalovirus inhibition of extrinsic apoptosis determines fitness and resistance to cytotoxic CD8 T cells. Proc Natl Acad Sci U S A 117(23):12961\u201312968. https:\/\/doi.org\/10.1073\/pnas.1914667117","journal-title":"Proc Natl Acad Sci U S A"}],"updated-by":[{"DOI":"10.1007\/s12016-021-08884-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000}}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08868-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-021-08868-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08868-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T03:11:39Z","timestamp":1640661099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-021-08868-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":209,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8868"],"URL":"https:\/\/doi.org\/10.1007\/s12016-021-08868-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12016-021-08884-z","asserted-by":"object"}]},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"31 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12016-021-08884-z","URL":"https:\/\/doi.org\/10.1007\/s12016-021-08884-z","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review was performed according to applicable ethical guidelines, using previously published and publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}